Page 125 - 78_03

ESTUDIO
DE
UTILIZACIÓN
DE
DABIGATRÁN…

9. Granero,
J.
(2007).
Guía
de
profilaxis
tromboembólica
en
Cirugía
Ortopédica
y

Traumatología.
Grupo
de
Estudio
del
Tromboembolismo
de
la
SECOT.

Madrid,.

10.
Baser,
O.,
Supina,
D.,
Sengupta,
N.,
Wang,
L.,
Kwong,
L.
(2010).
Impact
of
postoperative

venous
thromboembolism
on
Medicare
recipients
undergoing
total
hip
replacement
or

total
knee
replacement
surgery.
Am
J
Health-­-Syst
Pharm,
67,
1438-­-1445.

11.
Ficha
Técnica
Pradaxa®.
Medicamentos
Autorizados
en
España
(Uso
humano).
Web
site:

http://www.ema.europa.eu/docs/es_ES/document_library/EPAR__Product_Information/

human/000829/WC500041059.pdf

12.
Eriksson
B.
I.,
Dahl,
O.
E.,
Rosencher,
N.,
Kurth,
A.
A.,
Niek
van
Dijk,
C.,
Frostick,
S.
P.,

Kalebo,
P.,
Christiansen,
A.
V.,
Hantel,
S.,
Hettiarachchi,
R.,
Schnee,
J.,
Buller,
H.
R.,

&
RE-­-
MODEL
Study
Group.
(2007).
Oral
dabigatran
etexilate
vs.
subcutaneous
enoxaparin
for

the
prevention
of
venous
thromboembolism
after
total
knee
replacement:
the
RE-­-MODEL

randomized
trial.
J
Thromb
Haemost,
5,
2178–2185.

13.
Eriksson,
B.
I.,
Dahl,
O.
E.,
Rosencher,
N.,
Kurth,
A.
A.,
Niek
van
Dijk,
C.,
Frostick,
S.
P.
&
RE-­-
NOVATE
Study
Group.
(2007).
Dabigatran
etexilate
versus
enoxaparin
for
prevention
of

venous
thromboembolism
after
total
hip
replacement:a
randomised,
double-­-blind,
non-­-
inferiority
trial
(RENOVA-­-TE).
Lancet,
370,
949–956.

14.
Lotke,
P.
A.,
&
Lonner,
J.
H.
(2005).
Deep
venous
thrombosis
prophylaxis:
better
living

through
chemistry-­-in
opposition.
J
Arthroplasty,
20,
15-­-17.

15.
Schulman,
S.,
&
Kearon,
C.
(2005).
Subcommitee
on
Control
of
Anticoagulation
of
the

Scientific
and
Standardization
Committee
of
the
International
Society
on
Thrombosis
and

Haemostasis.
Definition
of
major
bleeding
in
clinical
investigations
of
antihemostatic

medicinal
products
in
non-­-surgical
patients.
J
Thromb
Haemost,
3,
692-­-694.

16.
Stangier,
J.,
Rathgen,
K.,
Stähle,
H.,
Gansser,
D.,
&
Roth,
W.
(2007).
The
pharmacokinetics,

pharmacodynamics
and
tolerability
of
dabigatran
etexilate,
a
new
oral
direct
thrombin

inhibitor,
in
healthy
male
subjects.
Br
J
Clin
Pharmacol,
64,
292–303.

17.
Informe
mensual
sobre
medicamentos
de
Uso
Humano
y
Productos
Sanitarios.
(abril

2011).
Agencia
española
de
medicamentos
y
productos
sanitarios.
Web
site:

https://www.seguridadmedicamento.sanidadmadrid.org/home.aspx?accesoExterno=si&t
ipo=noticia&id=269

18.
CHMP
Assessment
Report
for
Pradaxa.
European
Medicines
Agency
(EMEA).
Ref:

EMA/CHMP/304146/2011.
Summary
of
opinion
(post-­-authorisation)
(April
2011)

Web

site:
:

http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/huma

n/000829/WC500105283.pdf

19.
Connolly,
S.,
Ezekowitz,
M.
D.,
&
Yusuf,
S.
(2009).
Dabigatran
versus
warfarin
in
patients

with
atrial
fibrillation.
N
Engl
J
Med,
361,
1139-­-1151.

NOTA
DEL
EDITOR

Este
trabajo
obtuvo
el
Premio
CINFA
en
el
concurso
científico
2011
de
la

Real
Academia
Nacional
de
Farmacia.

385